SCHEMBL21938865

SCHEMBL21938865

NNC1(C(F)(F)F)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21806803 0.88 DGAT1 (0.34)
Hydrochloric Acid SCHEMBL18988896 0.80 DGAT1 (0.30)
SCHEMBL15612914 0.69
SCHEMBL22395766 0.66 DGAT1 (0.31)
SCHEMBL21533191 0.63
SCHEMBL13684643 0.63
SCHEMBL27870565 0.63
SCHEMBL20899790 0.63
SCHEMBL20899726 0.61 DGAT1 (0.37)
SCHEMBL21789658 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025917-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-01-25 US disclosed
US-20240025917-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-01-25 US disclosed
CN-116917293-A Plasma kallikrein inhibitors 默沙东有限责任公司 2023-10-20 CN disclosed
US-20230303540-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2023-09-28 US disclosed
EP-4247372-A1 PLASMA KALLIKREIN INHIBITORS Merck Sharp & Dohme LLC (US) 2023-09-27 EP disclosed
WO-2022109161-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-05-27 WO disclosed
WO-2022109161-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-05-27 WO disclosed
WO-2022051337-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2022-03-10 WO disclosed
WO-2020081682-A1 DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-23 WO disclosed